Groups Sweat Scope Of High Court Gene Patent Ruling

Law360, New York (April 12, 2013, 8:51 PM EDT) -- The U.S. Supreme Court case set for argument Monday over whether isolated human genes can be patented has spurred heated debate in dozens of amicus briefs over how the court's ruling will impact the biotechnology industry, patient care and the patent system.

Medical groups and others supporting the challenge to Myriad Genetics Inc.'s patents on isolated breast cancer genes claim that genes are natural products and patents on them impede health care and  research. Intellectual property and biotechnology groups supporting Myriad claim that isolated DNA is...
To view the full article, register now.